CU23200A3 - Sal polimorfica - Google Patents
Sal polimorficaInfo
- Publication number
- CU23200A3 CU23200A3 CU20010293A CU20010293A CU23200A3 CU 23200 A3 CU23200 A3 CU 23200A3 CU 20010293 A CU20010293 A CU 20010293A CU 20010293 A CU20010293 A CU 20010293A CU 23200 A3 CU23200 A3 CU 23200A3
- Authority
- CU
- Cuba
- Prior art keywords
- polymorphic salt
- migraine
- lambda
- prescribed
- alpha
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title 1
- 102000035038 5-HT1 receptors Human genes 0.000 abstract 1
- 108091005478 5-HT1 receptors Proteins 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 238000010586 diagram Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
El presente invento trata de una forma polimorfica cristalina de un compuesto de formula (I) ESPACIO PARA ESTRUCTURA QUIMICA caracterizada por un diagrama de difraccion de rayos X en polvo, obtenido al utilizar la radiacion K-alfa 1 del cobre (lambda = 0,15046 nm), que presenta picos principales a 9, 28, 10, 38, 11, 37, 12, 40, 16, 84, 17, 46, 17, 53, 17, 78, 17, 98, 19, 48, 20, 70, 21, 29, 21, 45, 22, 21, 22, 64, 23, 08, 25, 20 y 25, 79. El invento se refiere tambiÉn a procedimientos para la preparacion de dicha forma, a composiciones farmacÉuticas que contienen la misma y a su uso en medicina, particularmente en el tratamiento de estados para los que se prescribe un agonista de receptores 5-HT1, tales como, por ejemplo, la migrana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9922963.5A GB9922963D0 (en) | 1999-09-28 | 1999-09-28 | Polymorphic salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23200A3 true CU23200A3 (es) | 2007-04-06 |
Family
ID=10861767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20010293A CU23200A3 (es) | 1999-09-28 | 2001-12-10 | Sal polimorfica |
Country Status (50)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060025387A1 (en) * | 1998-12-23 | 2006-02-02 | Cytoscan Sciences Llc | Compositions and methods for the treatment of disorders of the central and peripheral nervous systems |
| US8722668B2 (en) * | 1998-12-23 | 2014-05-13 | Daryl W. Hochman | Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders |
| US7214711B2 (en) * | 1998-12-23 | 2007-05-08 | Neurotherapeutics Pharma Llc | Method of treating migraine headache without aura |
| US8008283B2 (en) * | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| GB0018968D0 (en) * | 2000-08-02 | 2000-09-20 | Pfizer Ltd | Particulate composition |
| US7132549B2 (en) | 2003-05-30 | 2006-11-07 | Pfizer Inc. | Process |
| GB0312478D0 (en) * | 2003-05-30 | 2003-07-09 | Pfizer Ltd | Improved process |
| ES2727577T5 (en) * | 2004-12-03 | 2025-04-02 | Merck Sharp & Dohme Llc | Pharmaceutical composition containing an anti-nucleating agent |
| US20070149526A1 (en) * | 2005-10-17 | 2007-06-28 | Neurotherapeutics Pharma, L.L.C. | Diuretic and diuretic-like compound analogs |
| KR100814109B1 (ko) * | 2006-01-09 | 2008-03-14 | 한국생명공학연구원 | 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물 |
| TWI394753B (zh) | 2006-03-17 | 2013-05-01 | Otsuka Pharma Co Ltd | 新穎替妥牟拉（ｔｅｔｏｍｉｌａｓｔ）晶體 |
| WO2010116386A2 (en) * | 2009-04-08 | 2010-10-14 | Biophore India Pharmaceuticals Pvt. Ltd. | Novel polymorph of eletriptan hydrobromide and process for the preparation thereof |
| EP3970702A1 (en) | 2009-10-26 | 2022-03-23 | Merck Sharp & Dohme Corp. | Solid pharmaceutical compositions containing an integrase inhibitor |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559246A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc. | Indole derivatives |
| PL168919B1 (pl) * | 1990-10-15 | 1996-05-31 | Pfizer | Sposób wytwarzania nowych pochodnych indolu PL PL PL PL |
| US5559129A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
| US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5578612A (en) | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
| US5998462A (en) * | 1996-12-16 | 1999-12-07 | Allelix Biopharmaceuticals Inc. | 5-alkyl indole compounds |
| JP3350061B2 (ja) | 1997-07-03 | 2002-11-25 | ファイザー・インク | エレトリプタンヘミスルフェートおよびカフェインを含有する医薬組成物 |
-
1999
- 1999-09-28 GB GBGB9922963.5A patent/GB9922963D0/en not_active Ceased
-
2000
- 2000-07-25 TW TW089114850A patent/TWI265926B/zh not_active IP Right Cessation
- 2000-07-28 PA PA20008498901A patent/PA8498901A1/es unknown
- 2000-08-10 CO CO00059853A patent/CO5180567A1/es not_active Application Discontinuation
- 2000-09-14 BR BR0014272-7A patent/BR0014272A/pt not_active Application Discontinuation
- 2000-09-14 EE EEP200200171A patent/EE200200171A/xx unknown
- 2000-09-14 AU AU67213/00A patent/AU779580B2/en not_active Ceased
- 2000-09-14 DK DK00954864T patent/DK1233960T3/da active
- 2000-09-14 ES ES00954864T patent/ES2200911T3/es not_active Expired - Lifetime
- 2000-09-14 UA UA2002032432A patent/UA72272C2/uk unknown
- 2000-09-14 AP APAP/P/2002/002457A patent/AP2004A/en active
- 2000-09-14 HR HR20020270A patent/HRP20020270B1/xx not_active IP Right Cessation
- 2000-09-14 NZ NZ516093A patent/NZ516093A/xx unknown
- 2000-09-14 YU YU2602A patent/YU2602A/sh unknown
- 2000-09-14 SK SK398-2002A patent/SK3982002A3/sk unknown
- 2000-09-14 GE GE4699A patent/GEP20043365B/en unknown
- 2000-09-14 PL PL00354960A patent/PL354960A1/xx not_active IP Right Cessation
- 2000-09-14 IL IL14715400A patent/IL147154A/xx not_active IP Right Cessation
- 2000-09-14 KR KR10-2002-7003963A patent/KR100479897B1/ko not_active Expired - Fee Related
- 2000-09-14 HU HU0202821A patent/HUP0202821A3/hu unknown
- 2000-09-14 JP JP2001526529A patent/JP3795395B2/ja not_active Expired - Fee Related
- 2000-09-14 MX MXPA02003311A patent/MXPA02003311A/es active IP Right Grant
- 2000-09-14 CA CA002379572A patent/CA2379572C/en not_active Expired - Fee Related
- 2000-09-14 DE DE60004262T patent/DE60004262T2/de not_active Expired - Lifetime
- 2000-09-14 OA OA1200200077A patent/OA12024A/en unknown
- 2000-09-14 AT AT00954864T patent/ATE246185T1/de not_active IP Right Cessation
- 2000-09-14 CZ CZ2002971A patent/CZ2002971A3/cs unknown
- 2000-09-14 SI SI200030165T patent/SI1233960T1/xx unknown
- 2000-09-14 CN CNB00810798XA patent/CN1155594C/zh not_active Expired - Fee Related
- 2000-09-14 TR TR2002/00804T patent/TR200200804T2/xx unknown
- 2000-09-14 EA EA200200302A patent/EA004510B1/ru not_active IP Right Cessation
- 2000-09-14 PT PT00954864T patent/PT1233960E/pt unknown
- 2000-09-14 EP EP00954864A patent/EP1233960B1/en not_active Expired - Lifetime
- 2000-09-14 WO PCT/IB2000/001305 patent/WO2001023377A2/en not_active Ceased
- 2000-09-14 DZ DZ003254A patent/DZ3254A1/fr active
- 2000-09-14 HK HK03100144.2A patent/HK1048628B/zh not_active IP Right Cessation
- 2000-09-19 US US09/664,946 patent/US6369094B1/en not_active Expired - Fee Related
- 2000-09-25 EG EG20001216A patent/EG24143A/xx active
- 2000-09-26 PE PE2000001010A patent/PE20010662A1/es not_active Application Discontinuation
- 2000-09-26 AR ARP000105032A patent/AR025779A1/es active IP Right Grant
- 2000-09-26 GT GT200000159A patent/GT200000159A/es unknown
- 2000-09-26 MY MYPI20004476A patent/MY121170A/en unknown
- 2000-09-27 TN TNTNSN00187A patent/TNSN00187A1/fr unknown
-
2001
- 2001-12-10 CU CU20010293A patent/CU23200A3/es not_active IP Right Cessation
- 2001-12-19 BG BG106240A patent/BG65161B1/bg unknown
-
2002
- 2002-01-08 IS IS6223A patent/IS2162B/is unknown
- 2002-01-24 CR CR6561A patent/CR6561A/es not_active Application Discontinuation
- 2002-03-15 MA MA26556A patent/MA26821A1/fr unknown
- 2002-03-26 ZA ZA200202406A patent/ZA200202406B/en unknown
- 2002-03-26 NO NO20021525A patent/NO321936B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23200A3 (es) | Sal polimorfica | |
| AU2014306149B2 (en) | KDM1A inhibitors for the treatment of disease | |
| RU2425041C2 (ru) | Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она | |
| ES2214434T3 (es) | Forma cristalina alfa de la sal de terc-butilamina de perindopril. | |
| AR029570A1 (es) | Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| HRP20160208T4 (hr) | Polimorfi dasatiniba i postupak za njihovu pripremu | |
| CU23713B7 (es) | Cristales anhidros que incluyen una sal del ácido málico de una 2-indolinona sustituida con 3-pirrol, métodos de preparación y composiciones que las contienen | |
| AR029571A1 (es) | Nueva forma cristalina beta de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| NO20063517L (no) | Ny krystallinsk form v av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den | |
| HU229358B1 (en) | Farnesyl protein transferase inhibitors for treating arthropathies | |
| RU2009131727A (ru) | Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения | |
| AR053147A1 (es) | Forma cristalina del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| BR0314338A (pt) | Substância cristalina para medicamento oral sólido e medicamento oral sólido para o tratamento de disúria contendo a mesma | |
| ES2614934T3 (es) | Nueva forma cristalina III de agomelatina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
| EP3790867A1 (en) | Kdm1a inhibitors for the treatment of disease | |
| NO20063518L (no) | Ny krystallinsk form IV av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den | |
| PE20030738A1 (es) | Sales de acido succinico de 5,7,14-triazatetraciclo[10.3.1.02,11.04,9] -hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas | |
| AR066158A1 (es) | COMPUESTO DE PIRIDAZINA CRISTALINA, UN MÉTODO PARA SU ELABORACIoN Y UNA COMPOSICIoN QUE LO COMPRENDE. | |
| AR017754A1 (es) | Macrolidas cristalinas, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento | |
| AR029347A1 (es) | Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica | |
| ECSP003681A (es) | Sal polimorfica | |
| RU2007130150A (ru) | Новая солевая форма агониста дофамина | |
| RU2813145C2 (ru) | Ингибиторы лизинспецифической гистондеметилазы 1A (KDM1A) для терапии заболеваний | |
| Park et al. | Synthesis of iodine‐123 labeled quercetin and catechin as radical seeking agents | |
| WO2025240390A1 (en) | Mary1 and derivatives thereof for the treatment of mitochondrial dysfunction, vascular injury, kidney diseases, and organ aging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse (for not paying fees) |